https://scholars.lib.ntu.edu.tw/handle/123456789/638447
Title: | Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors | Authors: | Bauer, Todd M Santoro, Armando CHIA-CHI LIN Garrido-Laguna, Ignacio Joerger, Markus Greil, Richard Spreafico, Anna Yau, Thomas Goebeler, Maria-Elisabeth Hütter-Krönke, Marie Luise Perotti, Antonella Juif, Pierre-Eric Lu, Darlene Barys, Louise Cremasco, Viviana Pelletier, Marc Evans, Helen Fabre, Claire Doi, Toshikiko |
Keywords: | Drug Therapy, Combination; Immunotherapy; Non-Small Cell Lung Cancer; Programmed Cell Death 1 Receptor; Therapies, Investigational | Issue Date: | 29-Nov-2023 | Journal Volume: | 11 | Journal Issue: | 11 | Source: | Journal for immunotherapy of cancer | Abstract: | NIS793 is a human IgG2 monoclonal antibody that binds to transforming growth factor beta (TGF-β). This first-in-human study investigated NIS793 plus spartalizumab treatment in patients with advanced solid tumors. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/638447 | ISSN: | 2051-1426 | DOI: | 10.1136/jitc-2023-007353 |
Appears in Collections: | 臨床醫學研究所 |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.